Ricker Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.34 M
- Company Age 38 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.14 M
- Revenue Growth 3.06%
- Profit Growth -14.24%
- Ebitda 0.98%
- Net Worth 13.40%
- Total Assets 14.97%
About Ricker Pharmaceuticals
Ricker Pharmaceuticals Pvt Ltd (RPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 June 1986 and has a history of 38 years and seven months. Its registered office is in Nadia, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.34 M.
The company currently has active open charges totaling ₹7.14 M.
Jhuma Bose and Narendra Bose serve as directors at the Company.
Company Details
-
Location
Nadia, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239WB1986PTC040787
-
Company No.
040787
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Jun 1986
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Ricker Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendra Bose
|
Managing Director | 22-May-1989 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Jhuma Bose
|
Director | 22-May-1989 | Current |
Financial Performance of Ricker Pharmaceuticals.
Ricker Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 3.06% increase. The company also saw a substantial fall in profitability, with a 14.24% decrease in profit. The company's net worth Soared by an impressive increase of 13.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ricker Pharmaceuticals?
In 2021, Ricker Pharmaceuticals had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.14 M
₹0
Charges Breakdown by Lending Institutions
- United Bank Of India : 0.71 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 May 2006 | United Bank Of India | ₹7.14 M | Open |
How Many Employees Work at Ricker Pharmaceuticals?
Ricker Pharmaceuticals has a workforce of 40 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ricker Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ricker Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.